{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:12:29Z","timestamp":1761894749714},"reference-count":24,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,10,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Imatinib mesylate (IM, Gleevec) has largely supplanted allogeneic hematopoietic cell transplantation (HCT) as first line therapy for chronic myeloid leukemia (CML). Nevertheless, many people with CML eventually undergo HCT, raising the question of whether prior IM therapy impacts HCT success. Data from the Center for International Blood and Marrow Transplant Research on 409 subjects treated with IM before HCT (IM+) and 900 subjects who did not receive IM before HCT (IM\u2212) were analyzed. Among patients in first chronic phase, IM therapy before HCT was associated with better survival but no statistically significant differences in treatment-related mortality, relapse, and leukemia-free survival. Better HLA-matched donors, use of bone marrow, and transplantation within one year of diagnosis were also associated with better survival. A matched-pairs analysis was performed and confirmed a higher survival rate among first chronic phase patients receiving IM. Among patients transplanted with advanced CML, use of IM before HCT was not associated with treatment-related mortality, relapse, leukemia-free survival, or survival. Acute graft-versus-host disease rates were similar between IM+ and IM\u2212 groups regardless of leukemia phase. These results should be reassuring to patients receiving IM before HCT.<\/jats:p>","DOI":"10.1182\/blood-2008-02-141689","type":"journal-article","created":{"date-parts":[[2008,7,30]],"date-time":"2008-07-30T03:40:04Z","timestamp":1217389204000},"page":"3500-3507","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":108,"title":["Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia"],"prefix":"10.1182","volume":"112","author":[{"given":"Stephanie J.","family":"Lee","sequence":"first","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, WA;"}]},{"given":"Manisha","family":"Kukreja","sequence":"additional","affiliation":[{"name":"Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee;"}]},{"given":"Tao","family":"Wang","sequence":"additional","affiliation":[{"name":"Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee;"}]},{"given":"Sergio A.","family":"Giralt","sequence":"additional","affiliation":[{"name":"M. D. Anderson Cancer Center, Houston, TX;"}]},{"given":"Jeffrey","family":"Szer","sequence":"additional","affiliation":[{"name":"Royal Melbourne Hospital, Parkville, Australia;"}]},{"given":"Mukta","family":"Arora","sequence":"additional","affiliation":[{"name":"University of Minnesota Medical Center, Minneapolis;"}]},{"given":"Ann E.","family":"Woolfrey","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, WA;"}]},{"given":"Francisco","family":"Cervantes","sequence":"additional","affiliation":[{"name":"Hospital Clinic, Barcelona, Spain;"}]},{"given":"Richard E.","family":"Champlin","sequence":"additional","affiliation":[{"name":"M. D. Anderson Cancer Center, Houston, TX;"}]},{"given":"Robert Peter","family":"Gale","sequence":"additional","affiliation":[{"name":"Center for Advanced Studies in Leukemia, Los Angeles, CA;"}]},{"given":"Joerg","family":"Halter","sequence":"additional","affiliation":[{"name":"University Hospital Basel, Basel, Switzerland;"}]},{"given":"Armand","family":"Keating","sequence":"additional","affiliation":[{"name":"Princess Margaret Hospital for Children, Toronto, ON;"}]},{"given":"David I.","family":"Marks","sequence":"additional","affiliation":[{"name":"Bristol Children's Hospital, Bristol, United Kingdom;"}]},{"given":"Philip L.","family":"McCarthy","sequence":"additional","affiliation":[{"name":"Roswell Park Cancer Institute, Buffalo, NY;"}]},{"given":"Eduardo","family":"Olavarria","sequence":"additional","affiliation":[{"name":"Hammersmith Hospital, London, United Kingdom;"}]},{"given":"Edward A.","family":"Stadtmauer","sequence":"additional","affiliation":[{"name":"Hospital of the University of Pennsylvania, Philadelphia;"}]},{"given":"Manuel","family":"Abecasis","sequence":"additional","affiliation":[{"name":"Instituto Portugues de Oncologia, Lisboa, Portugal;"}]},{"given":"Vikas","family":"Gupta","sequence":"additional","affiliation":[{"name":"Princess Margaret Hospital for Children, Toronto, ON;"}]},{"given":"H. Jean","family":"Khoury","sequence":"additional","affiliation":[{"name":"Emory University School of Medicine, Atlanta, GA;"}]},{"given":"Biju","family":"George","sequence":"additional","affiliation":[{"name":"Christian Medical College Hospital, Tamil Nadu, India;"}]},{"given":"Gregory A.","family":"Hale","sequence":"additional","affiliation":[{"name":"St Jude Children's Research Hospital, Memphis, TN;"}]},{"given":"Jane L.","family":"Liesveld","sequence":"additional","affiliation":[{"name":"University of Rochester Medical Center, NY;"}]},{"given":"David A.","family":"Rizzieri","sequence":"additional","affiliation":[{"name":"Duke University Medical Center, Durham, NC;"}]},{"given":"Joseph H.","family":"Antin","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA;"}]},{"given":"Brian J.","family":"Bolwell","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Foundation, OH;"}]},{"given":"Matthew H.","family":"Carabasi","sequence":"additional","affiliation":[{"name":"Thomas Jefferson University Hospital, Philadelphia, PA;"}]},{"given":"Edward","family":"Copelan","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Foundation, OH;"}]},{"given":"Osman","family":"Ilhan","sequence":"additional","affiliation":[{"name":"Ibni Sinai Hospital, Ankara, Turkey;"}]},{"given":"Mark R.","family":"Litzow","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, MN;"}]},{"given":"Harold C.","family":"Schouten","sequence":"additional","affiliation":[{"name":"University Hospital Maastricht, Maastricht, The Netherlands;"}]},{"given":"Axel R.","family":"Zander","sequence":"additional","affiliation":[{"name":"University Hospital Eppendorf, Hamburg, Germany; and"}]},{"given":"Mary M.","family":"Horowitz","sequence":"additional","affiliation":[{"name":"Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee;"}]},{"given":"Richard T.","family":"Maziarz","sequence":"additional","affiliation":[{"name":"Oregon Health & Science University, Portland"}]}],"member":"234","reference":[{"key":"2019111612240095800_B1","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1182\/blood.V95.7.2219","article-title":"Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the national marrow donor program.","volume":"95","author":"McGlave","year":"2000","journal-title":"Blood"},{"key":"2019111612240095800_B2","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"2019111612240095800_B3","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"2019111612240095800_B4","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1182\/blood-2007-04-038943","article-title":"How I treat chronic myeloid leukemia in the imatinib era.","volume":"110","author":"Goldman","year":"2007","journal-title":"Blood"},{"key":"2019111612240095800_B5","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1182\/blood-2006-11-055186","article-title":"Drug treatment is superior to allografting as first line therapy in chronic myeloid leukemia.","volume":"109","author":"Hehlmann","year":"2007","journal-title":"Blood"},{"key":"2019111612240095800_B6","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1365-2141.2007.06582.x","article-title":"Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia.","volume":"137","author":"Giralt","year":"2007","journal-title":"Br J Haematol"},{"key":"2019111612240095800_B7","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/sj.bmt.1705190","article-title":"The early referral for reduced-intensity stem cell transplantation in patients with Ph1 (+) chronic myelogenous leukemia in chronic phase in the imatinib era: results of the Latin American Cooperative Oncohematology Group (LACOHG) prospective, multicenter study.","volume":"36","author":"Ruiz-Arguelles","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"2019111612240095800_B8","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/sj.leu.2404509","article-title":"Hematopoietic stem cell transplants for chronic myeloid leukemia in Europe: impact of cost considerations.","volume":"21","author":"Gratwohl","year":"2007","journal-title":"Leukemia"},{"key":"2019111612240095800_B9","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2007-07-103523","article-title":"Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-\u03b1 treatment.","volume":"111","author":"Hochhaus","year":"2008","journal-title":"Blood"},{"key":"2019111612240095800_B10","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1056\/NEJM199804023381405","article-title":"Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia [see comments].","volume":"338","author":"Hansen","year":"1998","journal-title":"N Engl J Med"},{"key":"2019111612240095800_B11","first-page":"513","article-title":"Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).","volume":"91","author":"Gratwohl","year":"2006","journal-title":"Haematologica"},{"key":"2019111612240095800_B12","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"2019111612240095800_B13","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/nm1446","article-title":"Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.","volume":"12","author":"Kerkela","year":"2006","journal-title":"Nat Med"},{"key":"2019111612240095800_B14","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1182\/blood-2003-12-4266","article-title":"Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo.","volume":"104","author":"Dietz","year":"2004","journal-title":"Blood"},{"key":"2019111612240095800_B15","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/sj.leu.2402808","article-title":"Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias.","volume":"17","author":"Shimoni","year":"2003","journal-title":"Leukemia"},{"key":"2019111612240095800_B16","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/sj.bmt.1705087","article-title":"Imatinib therapy before myeloablative allogeneic stem cell transplantation.","volume":"36","author":"Zaucha","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"2019111612240095800_B17","first-page":"1145","article-title":"Imatinib preceding allogeneic stem cell transplantation in chronic myeloid leukemia.","volume":"91","author":"Perz","year":"2006","journal-title":"Haematologica"},{"key":"2019111612240095800_B18","first-page":"452","article-title":"The effect of prior exposure to imatinib on transplant-related mortality.","volume":"91","author":"Deininger","year":"2006","journal-title":"Haematologica"},{"key":"2019111612240095800_B19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.0902-4441.2005.t01-1-EJH2321.x","article-title":"Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study.","volume":"76","author":"Bornhauser","year":"2006","journal-title":"Eur J Haematol"},{"key":"2019111612240095800_B20","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1182\/blood-2006-06-031682","article-title":"The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia.","volume":"109","author":"Oehler","year":"2007","journal-title":"Blood"},{"key":"2019111612240095800_B21","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0140-6736(98)03030-X","article-title":"Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation: Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.","volume":"352","author":"Gratwohl","year":"1998","journal-title":"Lancet"},{"key":"2019111612240095800_B22","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","article-title":"Estimation of failure probabilities in the presence of competing risks: new representations of old estimators.","volume":"18","author":"Gooley","year":"1999","journal-title":"Stat Med"},{"key":"2019111612240095800_B23","doi-asserted-by":"crossref","DOI":"10.1007\/b97377","volume-title":"Survival Analysis: Statistical Methods for Censored and Truncated Data","author":"Klein","year":"2003"},{"key":"2019111612240095800_B24","doi-asserted-by":"crossref","first-page":"4288","DOI":"10.1182\/blood-2006-05-024042","article-title":"Long-term outcome of patients given transplants of mobilized blood or bone marrow: a report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation.","volume":"108","author":"Schmitz","year":"2006","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/112\/8\/3500\/1307749\/zh802008003500.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/112\/8\/3500\/1307749\/zh802008003500.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T10:09:57Z","timestamp":1588846197000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/112\/8\/3500\/114950\/Impact-of-prior-imatinib-mesylate-on-the-outcome"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10,15]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2008,10,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2008-02-141689","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,10,15]]}}}